Characteristic | IPAH patients (n = 41) | Control subjects (n = 50) |
---|---|---|
Age, years | 46.1 ± 17.6 | 48.3 ± 14.3 |
Male/Female, n | 14/27 | 20/30 |
Nonsurvivors, n | 12 | 0 |
BMI, kg/m2 | 22.8 ± 4.4 | – |
NT-proBNP, pg/mL | 797 (296–3035) | – |
WHO-FC III/IV, n (%) | 25 (59.2) | – |
6MWD, m | 362.2 ± 109.7 | – |
mRAP, mmHg | 6.0 ± 5.1 | – |
mPAP, mmHg | 56.2 ± 18.6 | – |
mPAWP, mmHg | 8.3 ± 4.0 | – |
PVR, Wood units | 15.8 ± 13.5 | – |
CO, L/min | 3.5 ± 1.4 | – |
Specific therapy, n (%) | Â | Â |
PDE-5 inhibitors | 10 (24.4) | – |
ERAs | 10 (24.4) | – |
sGC stimulator | 2 (4.9) | – |
Combination | 19 (46.3) | – |